HOME >> BIOLOGY >> NEWS
Federal testing for mad cow disease a failure, law review editor says

gency and the beef industry from a public outcry that would take place if more cases of mad cow disease were found. "In its 93 years of existence, the Virus-Serum-Toxin Act has never been used or interpreted to regulate testing of any kind. Manipulating the act to include the BSE test perverts the statute's purpose."

Congress should pass legislation forcing the USDA to license BSE tests to ranchers and slaughterhouses. "The USDA should create standards for testing conditions and requirements, and promulgate an application process with objective criteria for private producers. A standard testing regime would enable private producers such as Creekstone to market their beef as 'tested for BSE.'"

Berlowitz cited news reports that the cost of such testing would add only 6 to 10 cents to a pound of beef.

His article further warns of poor oversight of cattle feed. In particular, the slaughterhouse practice of "rendering," or recycling dead cows and sheep into protein for cattle feed, is believed to be widespread.

Congress banned the practice in 1997 following evidence that feeding herbivorous cows the meat from dead animals can lead to the formation of abnormal proteins, or prions.

The prions attack a cow's brain tissue, causing holes to form. As the brain loses function, the cow becomes disoriented and clumsy. Eventually the animal loses all muscle control and is unable to walk or eat. No treatment is available.

Enforcement of cattle-feed restrictions was placed in the hands of the Food and Drug Administration (FDA) rather than the USDA, which has caused various bureaucratic snarls, including a lack of communication between the two agencies.

"The FDA is far behind on inspecting feed businesses subject to the feed ban, has no uniform plan to identify feed businesses, has no routine procedure for testing of cattle feed, does not require a notice about the ban to be placed on feed, and has repeatedly failed to noti
'"/>

Contact: Mark Reutter, Business & Law Editor
mreutter@uiuc.edu
217-333-0568
University of Illinois at Urbana-Champaign
15-May-2006


Page: 1 2 3 4

Related biology news :

1. SNM opposes new payment caps on imaging services detailed in Federal Deficit Reduction Act
2. Pioneering ecologist Ruth Patrick honored by Federal-State Commission
3. ORNL technologies win maximum Federal Laboratory Consortium awards
4. Federal/private partners launch resource for diabetic kidney disease gene studies
5. Modular leukemia drug shows promise in early testing
6. Rapid syphilis testing in Haiti will prevent congenital disease and stillbirths
7. XDx to present recent success with AlloMap molecular expression testing
8. Potential genetic testing for substance abuse raises hope, concern
9. U-M team: Genetic testing sheds light on degenerative eye disease
10. Antiretroviral resistance testing in HIV infected patients improves health and saves costs
11. Professors to develop hand-held pathogen testing device

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Federal testing for mad cow disease failure law review editor says

(Date:6/18/2015)... 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market announces that its Wocket® smart ... "Money on the Mark", scheduled to air on WABC Radio ... 20 th . The broadcast air- time ... to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
(Date:6/17/2015)... GARDENS, Fla. , June 17, 2015 /PRNewswire/ ... solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... casual sandwich chain, to increase security, improve accountability ... fingerprint readers enable instant, non-repudiable identity confirmation for ...
(Date:6/16/2015)... Sweden , June 16, 2015 ... from previously communicated that it will amount to at least ... MSEK. Due to the rapid increase in market growth and ... the previously communicated guidance that revenue for 2015 will exceed ... will amount to approximately 2,200 MSEK. Due to ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
(Date:6/30/2015)... BOSTON , June 30, 2015  Juniper ... company focused on developing therapeutics that address unmet ... CFO George Elston will present at ... , Wednesday, July 8, 2015Time: , 4:45 PM ... NYWebcast (live & archive): , www.juniperpharma.com, under  ...
(Date:6/30/2015)... ... June 30, 2015 , ... With its latest polyacrylonitrile ... to achieve faster flow rates in comparison to nylon or polyethersulfone (PES). ... to allow easy liquid flow while trapping particulates as small as 0.2 micron ...
(Date:6/30/2015)... , ... June 30, 2015 , ... Matrix Marketing ... that it has hired Gem Swartz to head up its account management department as ... director. Both Gem and Amanda bring senior account management and delivery expertise to the ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... participant in its Phase 1/2 clinical trial of ... unilateral Achilles tendinosis, has been enrolled and their ... ultrasound-guided injections. RCT-01 is comprised of non-bulbar dermal ...
Breaking Biology Technology:Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Matrix Marketing Group Expands Client Services Team 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
Cached News: